Literature DB >> 2987382

Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.

E D Sprengers, H M Princen, T Kooistra, V W van Hinsbergh.   

Abstract

Primary cultures of human hepatocytes and the human hepatocellular cell line Hep G2 are shown to produce fast-acting inhibitors of tissue-type plasminogen activator (tPA) and urokinase. The tPA inhibitory activities in conditioned medium of these liver cell types are very similar to those present in human endothelial cell conditioned medium. They are stable at pH 2.5, have similar dissociation constants with tPA (1.5 to 5 pmol/L), and are similar in thermostability. Addition of tPA to conditioned medium of Hep G2 and endothelial cells that has been depleted of tPA and urokinase reveals a 100 kilodalton tPA-inhibitor complex. The fast-acting tPA inhibitory activity in human plasma has comparable properties, and may originate from the liver or the vascular endothelium or both. After sodium dodecyl sulfate-polyacrylamide gel electrophoresis of conditioned medium from hepatocytes, Hep G2, and endothelial cells, additional fibrinolytic inhibition at 52 kilodaltons was visualized. This was not found with human plasma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987382

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  23 in total

1.  Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells.

Authors:  T Kooistra; J van den Berg; A Töns; G Platenburg; D C Rijken; E van den Berg
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

2.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

3.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells.

Authors:  D Ginsburg; R Zeheb; A Y Yang; U M Rafferty; P A Andreasen; L Nielsen; K Dano; R V Lebo; T D Gelehrter
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

4.  Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome.

Authors:  S Idell; K K James; E G Levin; B S Schwartz; N Manchanda; R J Maunder; T R Martin; J McLarty; D S Fair
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.

Authors:  M A Haj; L A Robbie; A Croll; G D Adey; B Bennett
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

6.  Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage.

Authors:  S Idell; J Peters; K K James; D S Fair; J J Coalson
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

7.  Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases.

Authors:  P Fitch; B Bennett; N A Booth; A Croll; S W Ewen
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

8.  Ketoconazole blocks bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat by inhibiting cholesterol 7 alpha-hydroxylase.

Authors:  H M Princen; C M Huijsmans; F Kuipers; R J Vonk; H J Kempen
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

9.  Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy.

Authors:  J Schneiderman; M Sawdey; H Craig; T Thinnes; G Bordin; D J Loskutoff
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

10.  The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression.

Authors:  B A Konkle; D Ginsburg
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.